Introduction
Acute myocardial infarction (AMI) is one of the most fateful diseases in China [1] . With the development of cardiac intervention therapy, percutaneous coronary intervention (PCI) has become a crucial treatment to restore the blood flow in early stage [2] . However, there are still 10%-30% of the patients that suffer ischemia-reperfusion injury (IRI) after PCI treatment. Consequently, the size of myocardial infarction was expanded due to the apoptosis [3] and autophagy [4] caused by IRI. Therefore, discovering more effective drugs for reducing ischemia-reperfusion injury and keeping the vitality of myocardial cells is necessary.
Interleukin-6 (IL-6) was originally identified as B-cell stimulatory factor 2 that promotes immunoglobulin synthesis by activated B cells [5] . is not expressed in healthy persons, but when infections or tissue injuries occur, is rapidly synthesized and contributes to host defense [6] . However, excessive production of IL-6 during this process has been implicated in the development of acute, severe complications, including systemic inflammatory response syndrome (SIRS) and cytokinerelease syndrome (CRS) [7] . Recent studies showed that the expression of and its receptor was significantly increased during Acute myocardial ischemia-reperfusion (AMI/R) period and appeared a prognostic relevance for patients who experienced AMI [8] . Tocilizumab(Trade name: ACTEMRA@) is a humanized monoclonal antibody directed against interleukin-6 receptor. The molecule was humanized by the grafting of the complementaritydetermining regions of a mouse anti-human IL-6 receptor mAb onto human IgG1. It inhibits the binding of 
to its
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In this study, we demonstrated that tocilizumab displayed a protective effect for human cardiac myocytes after ischemia-reperfusion injury. Tocilizumab could suppress apoptosis and keep vitality of human cardiac myocytes after ischemia-reperfusion injury partly through down-regulating Bcl-2 and up-regulating Bax expression in vitro.
Materials and methods

Cell culture
The human cardiac myocytes were obtained from the ScienCell Research Laboratories (Carlsbad, California, USA). Cells were cultured in complete Dulbecco's modified Eagle medium (DMEM, Mediatech, USA) containing 10% fetal bovine serum (FBS, Gibco BRL, USA) in a humidified containing of 5% CO 2 incubator at 37 曟 . The logarithmic growth phase cells were harvested for further assays.
Tocilizumab intervention process
The Tocilizumab (Roche, Switzerland) was diluted with 1 暳 DMEM medium and adjusted the density of 1.0 mg/mL, 3 .0 mg/mL and 5.0 mg/mL, respectively. human cardiac myocytes were seeded in 6-well plates at the concentration of 1 暳 10 6 /well, and divided into four groups, describing as negative control group (NC Group, DMEM only), Test A group (Tocilizumab 1.0 mg/mL), Test B group (Tocilizumab 3.0 mg/mL), Test C group (Tocilizumab 5.0 mg/mL). Cells were intervened with different densities of tocilizumab or DMEM, and cultured in a humidified containing 5% CO 2 incubator at 37 曟 . Cells were harvest after 24 h intervention, and then used for further experiments.
Establishment of model of acute ischemia and reperfusion of human cardiac myocytes
The simulated ischemia reagent and reperfusion reagent were prepared according to the manufacture, that Ross et al previously reported [13] . The intervened human cardiac myocytes were washed by PBS for twice. Cells were added with 3 mL simulated ischemia reagent and cultured in a humidified containing 5% CO 2 and 95% N 2 incubator at 37 曟 for 24 h. 3 mL simulated reperfusion reagent was used to replace the simulated ischemia reagent, and cultured the cells in normal environment for 1 h.
MTT assay
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT, Roche, USA) assay was used to determine the proliferation viability. Cell viability was calculated at 24 h, 48 h and 72 h after ischemia simulation and reperfusion intervention. The absorbance of the samples was measured using a model 550 microplate reader (Bio-Rad Laboratories, USA), at a wavelength of 490 nm. Three independent experimental replicates were performed.
Cell apoptosis detection
Annexin-V-FLUOS Staining Kit (Roche, USA) was purchased to evaluate cell apoptosis after 48h intervention. Briefly, the samples were analyzed by BD FACS Canto 栻 Flow Cytometer (Becton Dickinson, USA). Three independent experimental replicates were performed.
qRT-PCR
Total RNA was isolated from human cardiac myocytes, which underwent simulated ischemia and reperfusion i n t e r v e n t i o n , b y T R I Z O L 襆 r e a g e n t ( I n v i t r o g e n , USA) according to the manufacturer. The following primers were synthesized: Bcl-2 sense primer 5'-CCTTTGTGTAACTGTACGGCC-3' and anti-sense primer 5'-CTTTGGCAGTAAATAGCTGATTCGAC-3', Bax sense primer 5'-TCCACCAAGAAGCTGAGCGAG-3' and anti-sense primer 5'-GTCCAGCCCATGATGGTTCT-3', 毬 -actin sense primer 5'-CTCCATCCTGGCCTCGCTGT-3' and anti-sense primer 5'-GCTGTCACCTTCACCGTTCC -3'. Reverse 
Western blot assay
Human anti-rabbit Bcl-2(SC-7382, Santa Cruz, USA) (1:1 000), Bax(SC-7480, Santa Cruz, USA) (1:1 000) and human anti-mouse 毬 -actin (Santa Cruz, USA) (1:5 000) antibodies were used for western blot assay. Secondary horseradish peroxidase-conjugated goat anti-mouse or -rabbit antibody (Bio-Rad, USA) were used at a 1:5 000 dilution. The relative protein concentration were measured by gray value, which was displayed by the Enhanced Chemiluminescence Regent (Millipore, USA).
Statistic analysis
All date are presented as (Mean 暲 SD). Two-tailed Student's t test or ANOVA was used to evaluate statistical significant using GraphPad Prism 5 software (GraphPad Software, Inc). P<0.05 was considered as statistically significant different.
Results
Proliferation viability of tocilizumab intervened human cardiac myocytes after IRI
Compared to the NC group, cells intervened by tocilizumab appeared a higher proliferation viability after underwent IRI 
Apoptosis of tocilizumab intervened human cardiac myocytes after IRI
As shown in Figure 2 , tocilizumab could effectively 
Expression changes of Bcl-2 and Bax in tocilizumab intervened human cardiac myocytes after IRI
According to the results shown above, tocilizumab could keep proliferation viability and resist apoptosis of human cardiac myocytes after IRI. To investigate the possible molecular mechanisms, the mRNA and protein levels of Bcl-2 and Bax were detected, which were two classic genes in cell growth regulation, in each test or NC group cells by qRT-PCR and western blot. Both mRNA and protein levels of Bcl-2 were more significantly up-regulated in test groups than in NC group (P<0.05, Figure 3A and 3C), in the meanwhile, the expression levels of Bax were more significantly down-regulated in test groups than in NC group (P<0.05, Figure 3B and 3C). Furthermore, within the test groups, the mRNA and protein levels of Bcl-2 were higher, while Bax were lower, in 3 mg/mL group than in 1 mg/mL group (P<0.05), but there was no significant change between 3 mg/mL group and 5 mg/mL group (P>0.05).
Discussion
AMI is the most common complications of coronary heart disease. Recently, the incidence of AMI rises every year in our country. Restoring myocardial blood flow as quickly as possible is one of the most crucial process to improve the prognosis of AMI patients [14] . At the same time, how to reduce or avoid the IRI becomes an overarching concern for all doctors. Nowadays, many of interleukins such as IL-1[ 15] , IL-8 [16] , IL-10 [17] and IL-17A [18] , has been demonstrated to activate and participate in IRI of myocardium after AMI/R. IL-6 serve as an important factor in several inflammatory processes, and it can lead to a so called "waterfall effect" of inflammation [19] , and eventually induce apoptosis and disintegration of certain cells. Recently, studies found that IL-6 of myocardium was significant elevated in IRI group compared to ischemic preconditioning group and positive associated with the infarct size in rat AMI/R model [20] . Zhao et al reported that atorvastatin could reduce myocardium necrosis area in a rabbit model of AMI/R through downregulating the serum IL-6 level [21] . These evidences suggest that IL-6 could serve as a therapeutic target to prevent IRI of myocardium. This led to the development of tocilizumab, a humanized monoclonal antibody, with the CDR of a mouse anti-IL-6R grafted on to human IgG1 molecule. Tocilizumab can block both classic and trans-signaling pathways by inhibiting IL-6 binding to transmembrane IL-6R and soluble IL-6R.
In this study, we treated human cardiac myocytes with different concentrations of tocilizumab, and detected the tolerance of human cardiac myocytes to AMI/R. Firstly, we used MTT assay to detect cell proliferation viability, and found that tocilizumab could prominently keep the proliferation activity of human cardiac myocytes after AMI/ R. Furthermore, the results of flow cytometry demonstrated that tocilizumab also could inhibit human cardiac myocytes apoptosis after AMI/R. Interestingly, we found that cells treated with 3 mg/mL tocilizumab could gain a better protective effect than 1mg/mL, but no more improvement when the concentration evaluate to 5 mg/mL. This means that the protective effect has a character of saturability, and the reason may be that the binding of antigen to antibody has reached saturation. In order to realize the molecular mechanisms of these effects, we detected two classic growth regulation genes, Bcl-2 and Bax. The expression of Bcl-2 was up-regulation, while the expression of Bax was downregulation, in test groups compared to the NC group. In accordance with the functional results, these changes could be enlarged with the increasing concentrations of tocilizumab from 1 mg/mL to 3 mg/mL, but no more expansion observed when the concentrations of tocilizumab continuously increased to 5mg/mL. It has been proved that IL-6 combined with IL-6R could phosphorylate STAT1 to p-STAT1 in Ser-727 position, and p-STAT1 served as a cotransactivator for enhancing the transcription of Bax [22, 23] . Tocilizumab could competitive bind with IL-6R and block the phosphorylation of STAT1, then regulating the expression of Bax and Bcl-2. That may partly explain the results we obtained.
In conclusion, tocilizumab could significantly suppress the apoptosis and keep the proliferation viability of human cardiac myocytes after AMI/R.tocilizumab has wide application prospects in the protection of myocardium ischemia reperfusion
Conflict of interest statement
We declare that we have no conflict of interest. [2] Neskovic AN, Stankovic I, Milicevic P, Aleksic A, Vlahovic- Figure 3 . Tocilizumab regulates the expression of Bcl-2 and Bax in human cardiac myocytes after AMI/R. The Bcl-2 (A) and Bax (B) mRNA levels of each group were determined by qRT-PCR. n=3. Data show representative results of repeat experiments. *P<0.05. The Bcl-2and Bax protein levels of each group were determined by western blot (C).
References
